Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Insmed

Insmed (NASDAQ: INSM) insider transactions

In the twelve months to 10 November 2026, executives and directors of Insmed reported 161 open-market sales of 1,070,006 shares ($162.1m) and 0 open-market purchases, by 10 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Insmed shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
19 October 2026Koppikar UtpalDirectorGrant or award+6,139—6,139Form 4
19 October 2026Hudson PaulDirectorGrant or award+6,139—6,139Form 4
9 September 2026Brennan David RDirectorOpen-market sale−25,000$124.0039,238Form 4
17 August 2026Sharoky Melvin MDDirectorOpen-market sale−5,000$127.530Form 4
10 August 2026Adsett RogerChief Operating OfficerOption exercise+82,280$13.67181,024Form 4
10 August 2026Adsett RogerChief Operating OfficerOption exercise+76,600$17.16257,624Form 4
10 August 2026Adsett RogerChief Operating OfficerOption exercise+80,970$30.46338,594Form 4
10 August 2026Adsett RogerChief Operating OfficerOpen-market sale−239,850$133.2798,744Form 4
6 August 2026Flammer Martina M.D.Chief Medical OfficerOption exercise, 10b5-1 plan+18,278$18.9578,764Form 4
6 August 2026Flammer Martina M.D.Chief Medical OfficerOption exercise, 10b5-1 plan+8,895$25.8387,659Form 4
6 August 2026Flammer Martina M.D.Chief Medical OfficerOpen-market sale, 10b5-1 plan−8,895$127.0078,764Form 4
6 August 2026Flammer Martina M.D.Chief Medical OfficerOpen-market sale, 10b5-1 plan−18,278$129.4060,486Form 4
23 July 2026Lewis WilliamChair and CEOOption exercise, 10b5-1 plan+6,260$30.46265,318Form 4
23 July 2026Lewis WilliamChair and CEOOption exercise, 10b5-1 plan+4,440$17.16269,758Form 4
23 July 2026Lewis WilliamChair and CEOOpen-market sale, 10b5-1 plan−4,828$105.62264,930Form 4
23 July 2026Lewis WilliamChair and CEOOpen-market sale, 10b5-1 plan−5,872$106.43259,058Form 4
9 July 2026Lewis WilliamChair and CEOOption exercise, 10b5-1 plan+6,259$30.46265,317Form 4
9 July 2026Lewis WilliamChair and CEOOption exercise, 10b5-1 plan+4,440$17.16269,757Form 4
9 July 2026Lewis WilliamChair and CEOOpen-market sale, 10b5-1 plan−5,005$116.55264,752Form 4
9 July 2026Lewis WilliamChair and CEOOpen-market sale, 10b5-1 plan−2,335$117.62262,417Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Insmed page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.